Related Experiment Videos
Chemotherapy of acute myeloblastic leukaemia with DAM regimen
A B Yunus1, M A Sayeed, A Barua
1Department of Haematology, Institute of Postgraduate Medicine & Research, Dhaka.
Bangladesh Medical Research Council Bulletin
|June 11, 1998
Abstract:
32 patients of denovo-ANLL were treated with Doxorubicin, Ara-C and 6-Mercaptopurine (DAM) regimen. Remission induction was instituted with 1-3 cycles of DAM regimen and maintenance was given by 6-MP continuously with intermittent DA (1,5) regimen. In the remission induction, Doxorubicin 30 mg/m2 for 3 days, Ara-C 150 mg/m2 for 5 days and 6-Mp 100 mg/m2 daily was given. Complete remission (CR) was observed in 60% cases. The probability of 2 years disease-free survival of patients with complete remission is 56.73%.